<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02851277</url>
  </required_header>
  <id_info>
    <org_study_id>0892-CL-1001</org_study_id>
    <nct_id>NCT02851277</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine</brief_title>
  <official_title>A Phase 1, Randomized, Placebo Controlled Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA LAMP Vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Global Development, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of ASP0892 after&#xD;
      intradermal or intramuscular injection in adults with peanut allergy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 13, 2016</start_date>
  <completion_date type="Actual">December 6, 2018</completion_date>
  <primary_completion_date type="Actual">December 6, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as assessed by number of participants with Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to Day 360</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by Vital sign: body temperature</measure>
    <time_frame>Up to Day 360</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by Vital sign: blood pressure</measure>
    <time_frame>Up to Day 360</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by Vital sign: pulse rate</measure>
    <time_frame>Up to Day 360</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by 12- lead Electrocardiograms (ECGs)</measure>
    <time_frame>Up to Day 360</time_frame>
    <description>The overall conclusion will be recorded as normal and abnormal (not clinically significant/ clinically significant).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by Laboratory test: hematology</measure>
    <time_frame>Up to Day 360</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by Laboratory test: biochemistry</measure>
    <time_frame>Up to Day 360</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by Laboratory test: urinalysis</measure>
    <time_frame>Up to Day 360</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by Anti-Lysosomal associated membrane protein-1 (LAMP-1) antibody</measure>
    <time_frame>Up to Day 360</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Peanut Allergy</condition>
  <arm_group>
    <arm_group_label>Low dose ASP0892 Intradermal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive study drug once every 2 weeks for a total of 4 doses. After participants complete the Low dose arms, the Dose Escalation Committee (DEC) will determine if the study can progress to the parallel higher dose arms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose ASP0892 Intradermal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive study drug once every 2 weeks for a total of 4 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Intradermal</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive comparable Placebo once every 2 weeks for a total of 4 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose ASP0892 Intramuscular</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive study drug once every 2 weeks for a total of 4 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Intramuscular</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive comparable Placebo once every 2 weeks for a total of 4 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP0892 Intradermal</intervention_name>
    <description>Intradermal injection</description>
    <arm_group_label>High dose ASP0892 Intradermal</arm_group_label>
    <arm_group_label>Low dose ASP0892 Intradermal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP0892 Intramuscular</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>High dose ASP0892 Intramuscular</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Intradermal</intervention_name>
    <description>Intradermal injection</description>
    <arm_group_label>Placebo Intradermal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Intramuscular</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Placebo Intramuscular</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has a body mass index (BMI) ≥ 18 and 32 at screening.&#xD;
&#xD;
          -  Subject has a physician-diagnosed peanut allergy or history of peanut allergy.&#xD;
             Subjects with history of nonsevere anaphylaxis (Grade ≤ 3) to peanuts (including mild&#xD;
             wheezing or dyspnea without hypoxia) will be enrolled.&#xD;
&#xD;
          -  Subject has an anti-Ara h2 IgE measured by ImmunoCAP &gt; 0.35 kU/L.&#xD;
&#xD;
          -  Subject has a positive SPT to peanut with a change in wheal diameter ≥ 3 mm as&#xD;
             compared to a negative control.&#xD;
&#xD;
          -  Subject has a positive peanut double-blinded placebo-controlled food challenge&#xD;
             (DBPCFC) at Screen 2 visit with an eliciting dose ≤ 300 mg peanut protein (≤ 444 mg&#xD;
             cumulative reactive dose [CRD]).&#xD;
&#xD;
          -  Female subject must either:&#xD;
&#xD;
               -  Be of non-child bearing potential: post-menopausal (defined as at least 1 year&#xD;
                  without any menses) prior to screening, or documented surgically sterile.&#xD;
&#xD;
               -  Or, if of childbearing potential: Agree not to become pregnant during the study;&#xD;
                  and have a negative (urine) pregnancy test result at screening and at day 1&#xD;
                  (predose); and, if heterosexually active, agree to consistently use 2 forms of&#xD;
                  highly effective birth control (at least one of which must be a barrier method)&#xD;
                  starting at screening and throughout the study period.&#xD;
&#xD;
          -  Female subject must agree not to breastfeed starting at screening and throughout the&#xD;
             study period, and for 28 days after the final study drug administration.&#xD;
&#xD;
          -  Female subject must not donate ova starting at screening and throughout the study&#xD;
             period, and for 28 days after the final study drug administration.&#xD;
&#xD;
          -  Male subject and female spouse/partners who are of childbearing potential must be&#xD;
             using highly effective contraception consisting of two forms of birth control (at&#xD;
             least one of which must be a barrier method) starting at screening and continue&#xD;
             throughout the study period, and for 90 days after the final study drug&#xD;
             administration.&#xD;
&#xD;
          -  Male subject must not donate sperm starting at screening and throughout the study&#xD;
             period, and for 90 days after the final study drug administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has severe anaphylaxis to peanuts (Grades 4 or 5 including dyspnea associated&#xD;
             with hypoxia, cyanosis, hypotension, or neurological compromise) per the Grading of&#xD;
             Food-Induced Anaphylaxis According to Severity of Clinical Symptoms based on&#xD;
             historical clinical symptoms.&#xD;
&#xD;
          -  Subject develops a Grade 4 or 5 reaction during the DBPCFC.&#xD;
&#xD;
          -  Subject who has received or is planning to receive administration of any vaccine&#xD;
             (other than injectable Influenza vaccine) within 28 days prior to the administration&#xD;
             of the study vaccine or at any time during the study.&#xD;
&#xD;
          -  Subject who received any specific immunotherapy for allergy (e.g., epicutaneous&#xD;
             immunotherapy [EPIT], sublingual immunotherapy [SLIT], subcutaneous immunotherapy&#xD;
             [SCIT], and oral immunotherapy [OIT]) during the past 12 months, currently, or plans&#xD;
             to receive during the course of the study.&#xD;
&#xD;
          -  Subject who has used the following drug(s) prior to the dosing of the study vaccine:&#xD;
&#xD;
               -  Within 2 months prior to study vaccine administration: Systemic (or inhaled)&#xD;
                  steroid, chemical mediator-isolation inhibitor, Th2 cytokine inhibitor,&#xD;
                  thromboxane A2 synthesis inhibitor, thromboxane A2 receptor antagonist,&#xD;
                  β-blocker, angiotensin-converting enzyme inhibitors, and/or angiotensin-receptor&#xD;
                  blockers&#xD;
&#xD;
               -  Within 3 months prior to study vaccine administration: Biologics and/or immune&#xD;
                  modulators (including anti-TNFα antibody and anti-IgE monoclonal antibody)&#xD;
&#xD;
          -  Subject who has history of allergic reactions such as anaphylactic shock, angioedema&#xD;
             with airway constriction or hypotension caused by food other than peanut and/or&#xD;
             medical products (including vaccine) in the past.&#xD;
&#xD;
          -  Subject's laboratory test results at screening or prior to study vaccine dosing on day&#xD;
             1 are outside the normal limits and considered to be clinically significant.&#xD;
&#xD;
          -  Subject with anti-LAMP-1 antibodies above the cut-point for the Tier 1 assay and who&#xD;
             is confirmed positive in the Tier 2 assay at Screen 1 visit (baseline).&#xD;
&#xD;
          -  Subject who had a positive test results for hepatitis B surface (HBs) antigen,&#xD;
             hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) antigen/&#xD;
             antibody.&#xD;
&#xD;
          -  Subject who has immune disorders (including autoimmune disease) and/or diseases&#xD;
             requiring immunosuppressive drugs.&#xD;
&#xD;
          -  Subject who was diagnosed with immunodeficiency in the past.&#xD;
&#xD;
          -  Subject who has uncontrolled hypertension.&#xD;
&#xD;
          -  Subject who has a history of cardiovascular disease, arrhythmias, chronic lung&#xD;
             disease, active eosinophilic gastrointestinal disease, or any other medical or&#xD;
             surgical conditions which places the subject at increased risk for participation in&#xD;
             the study.&#xD;
&#xD;
          -  Subject who has a complication or medical history of respiratory disease which&#xD;
             requires medical treatment.&#xD;
&#xD;
          -  Subject who has a complication or medical history of malignant tumor.&#xD;
&#xD;
          -  Subject who has mental conditions such as schizophrenia, bipolar disorder, and major&#xD;
             depressive disorder, or a subject who has received drug(s) for the treatment of&#xD;
             dementia.&#xD;
&#xD;
          -  Subject who has severe or poorly controlled dermatitis atopic or generalized eczema.&#xD;
&#xD;
          -  Subject who is unable to discontinue antihistamines within 7 days or 5 half-lives&#xD;
             (whichever duration is longer) as follows:&#xD;
&#xD;
               -  prior to dosing through 7 days post last dose of study vaccine&#xD;
&#xD;
               -  prior to skin prick testing and oral food challenge procedures&#xD;
&#xD;
          -  Subject who has asthma other than mild intermittent asthma (National Heart, Lung, and&#xD;
             Blood Institute [NHLBI] guidelines) and has a FEV1 value &lt; 80% and/or requiring&#xD;
             chronic maintenance treatment (i.e., inhaled corticosteroids).&#xD;
&#xD;
          -  Subject who has already received vaccination of LAMP-vax such as ASP0892.&#xD;
&#xD;
          -  Subject who has received investigational therapy within 35 days or 5 half- lives&#xD;
             whichever is longer, prior to screening.&#xD;
&#xD;
          -  Subject who is an employee of the Astellas Group or vendors involved in the study.&#xD;
&#xD;
          -  Subject who has any condition which makes the subject unsuitable for study&#xD;
             participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Senior Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site US10014</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10008</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10001</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10002</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10004</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029-6574</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10003</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10012</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10006</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>July 28, 2016</study_first_submitted>
  <study_first_submitted_qc>July 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2016</study_first_posted>
  <last_update_submitted>December 4, 2019</last_update_submitted>
  <last_update_submitted_qc>December 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peanut Allergy</keyword>
  <keyword>ASP0892</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peanut Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under &quot;Sponsor Specific Details for Astellas.&quot;</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

